» Articles » PMID: 25009465

Parkinson's Disease-implicated Kinases in the Brain; Insights into Disease Pathogenesis

Overview
Specialty Molecular Biology
Date 2014 Jul 11
PMID 25009465
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Substantial evidence implicates abnormal protein kinase function in various aspects of Parkinson's disease (PD) etiology. Elevated phosphorylation of the PD-defining pathological protein, α-synuclein, correlates with its aggregation and toxic accumulation in neurons, whilst genetic missense mutations in the kinases PTEN-induced putative kinase 1 and leucine-rich repeat kinase 2, increase susceptibility to PD. Experimental evidence also links kinases of the phosphoinositide 3-kinase and mitogen-activated protein kinase signaling pathways, amongst others, to PD. Understanding how the levels or activities of these enzymes or their substrates change in brain tissue in relation to pathological states can provide insight into disease pathogenesis. Moreover, understanding when and where kinase dysfunction occurs is important as modulation of some of these signaling pathways can potentially lead to PD therapeutics. This review will summarize what is currently known in regard to the expression of these PD-implicated kinases in pathological human postmortem brain tissue.

Citing Articles

NERINE reveals rare variant associations in gene networks across multiple phenotypes and implicates an subnetwork in Parkinson's disease.

Nazeen S, Wang X, Morrow A, Strom R, Ethier E, Ritter D bioRxiv. 2025; .

PMID: 39829934 PMC: 11741352. DOI: 10.1101/2025.01.07.631688.


CK and LRRK2 Involvement in Neurodegenerative Diseases.

Bova V, Mannino D, Capra A, Lanza M, Palermo N, Filippone A Int J Mol Sci. 2024; 25(21).

PMID: 39519213 PMC: 11546471. DOI: 10.3390/ijms252111661.


Differential LRRK2 Signalling and Gene Expression in WT-LRRK2 and G2019S-LRRK2 Mouse Microglia Treated with Zymosan and MLi2.

Nazish I, Mamais A, Mallach A, Bettencourt C, Kaganovich A, Warner T Cells. 2024; 13(1).

PMID: 38201257 PMC: 10778119. DOI: 10.3390/cells13010053.


Involvement of casein kinase 1 epsilon/delta (Csnk1e/d) in the pathogenesis of familial Parkinson's disease caused by CHCHD2.

Torii S, Arakawa S, Sato S, Ishikawa K, Taniguchi D, Sakurai H EMBO Mol Med. 2023; 15(9):e17451.

PMID: 37578019 PMC: 10493588. DOI: 10.15252/emmm.202317451.


Mitochondrial Bioenergy in Neurodegenerative Disease: Huntington and Parkinson.

Tassone A, Meringolo M, Ponterio G, Bonsi P, Schirinzi T, Martella G Int J Mol Sci. 2023; 24(8).

PMID: 37108382 PMC: 10138549. DOI: 10.3390/ijms24087221.


References
1.
Meggio F, Pinna L . One-thousand-and-one substrates of protein kinase CK2?. FASEB J. 2003; 17(3):349-68. DOI: 10.1096/fj.02-0473rev. View

2.
Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

3.
Bergeron M, Motter R, Tanaka P, Fauss D, Babcock M, Chiou S . In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain. Neuroscience. 2013; 256:72-82. DOI: 10.1016/j.neuroscience.2013.09.061. View

4.
Li X, Geng J, Liu J . Adiponectin offers protection against L166P mutant DJ-1-induced neuronal cytotoxicity mediated by APPL1-dependent AMPK activation. Int J Neurosci. 2013; 124(5):350-61. DOI: 10.3109/00207454.2013.846340. View

5.
Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg M . alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002; 4(2):160-4. DOI: 10.1038/ncb748. View